Matched characteristics | CBDCA + GEM (n = 17) | CDDP + VNR (n = 17) | P |
---|---|---|---|
Median age, years (range) | 62 (47–70) | 59 (33–70) | 0.458 |
Gender (%) | Â | Â | 0.243 |
 Male | 14 (82.3) | 11 (64.7) |  |
 Female | 3 (17.6) | 6 (35.2) |  |
Surgical procedure (%) | Â | Â | 0.367 |
 Lobectomy | 17 (100.0) | 16 (94.1) |  |
 Pneumonectomy | 0 | 1 (5.8) |  |
ECOG performance status (%) | Â | 1 | |
 0 | 17 (100) | 17 (100) |  |
Pathological stage (%) | Â | Â | 0.922 |
 IIA | 2 (11.7) | 1 (5.8) |  |
 IIB | 3 (17.6) | 4 (23.5) |  |
 IIIA | 8 (47.0) | 8 (47.0) |  |
 IIIB | 4 (23.5) | 4 (23.5) |  |
Histology (%) | Â | Â | 0.871 |
 Adenocarcinoma | 14 (82.3) | 16 (94.1) |  |
 Squamous cell carcinoma | 3 (17.6) | 1 (5.8) |  |
Lymph nodal status (%) | Â | Â | 0.513 |
 N0 | 4 (23.5) | 2 (11.7) |  |
 N1 | 2 (11.7) | 4 (23.5) |  |
 N2 | 11 (64.7) | 11 (64.7) |  |
Number of course | Â | Â | 0.434 |
 1/2/3/4 | 1/0/1/15 | 2/0/3/12 |  |
EGFR mutation (%) | Â | Â | 0.831 |
 Negative/unknown | 14 (82.3) | 13 (76.4) |  |
 Positive | 3(17.6) | 4 (23.5) |  |
ALK fusion (%) | Â | Â | 0.310 |
 Negative/unknown | 17(100.0) | 16(94.1) |  |
 Positive | 0 | 1(5.8) |  |